{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:01:29Z","timestamp":1771549289958,"version":"3.50.1"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,7,1]]},"DOI":"10.2169\/internalmedicine.0882-22","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T22:13:00Z","timestamp":1667945580000},"page":"1965-1970","source":"Crossref","is-referenced-by-count":4,"title":["Kidney Podocyte Zebra Bodies after Lung Transplantation for Lymphangioleiomyomatosis"],"prefix":"10.2169","volume":"62","author":[{"given":"Takashi","family":"Ishide","sequence":"first","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinako","family":"Miyano","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Honda","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Tokyo Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The University of Tokyo Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry&apos;s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276: 1163-1167, 1967.","DOI":"10.1056\/NEJM196705252762101"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sawada J, Nakagawa N, Kano K, et al. Characteristics of neurological symptoms in adult Japanese patients with Fabry disease. Intern Med 60: 1819-1826, 2021.","DOI":"10.2169\/internalmedicine.6420-20"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Muto R, Inagaki K, Kato N, Maruyama S, Akahori T. The 30-year natural history of non-classic Fabry disease with an R112H mutation. Intern Med 61: 1727-1730, 2022.","DOI":"10.2169\/internalmedicine.8213-21"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry&apos;s disease with the pharmacologic chaperone migalastat. N Engl J Med 375: 545-555, 2016.","DOI":"10.1056\/NEJMoa1510198"},{"key":"5","unstructured":"5. Schiffmann R, Hughes DA, Linthorst GE, et al; Conference Participants. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a &quot;Kidney Disease: Improving Global Outcomes&quot; (KDIGO) Controversies Conference. Kidney Int 91: 284-293, 2017."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 13 Suppl 2: S134-S138, 2002.","DOI":"10.1097\/01.ASN.0000016684.07368.75"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. de Menezes Neves PDM, Machado JR, Custodio FB, et al. Ultrastructural deposits appearing as &quot;zebra bodies&quot; in renal biopsy: Fabry disease? - comparative case reports. BMC Nephrol 18: 157, 2017.","DOI":"10.1186\/s12882-017-0571-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Manabe S, Mochizuki T, Sato M, et al. Lupus nephritis and hydroxychloroquine-associated zebra bodies: not just in Fabry disease. Kidney Med 3: 442-446, 2021.","DOI":"10.1016\/j.xkme.2021.01.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Inoue T, Maekawa H, Inagi R. Organelle crosstalk in the kidney. Kidney Int 95: 1318-1325, 2019.","DOI":"10.1016\/j.kint.2018.11.035"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett 580: 5533-5540, 2006.","DOI":"10.1016\/j.febslet.2006.08.061"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel <i>in vitro<\/i> screening system. Toxicol Sci 83: 282-292, 2005.","DOI":"10.1093\/toxsci\/kfh264"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fischer H, Atzpodien EA, Csato M, et al. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. J Med Chem 55: 126-139, 2012.","DOI":"10.1021\/jm201082a"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Breiden B, Sandhoff K. Emerging mechanisms of drug-induced phospholipidosis. Biol Chem 401: 31-46, 2019.","DOI":"10.1515\/hsz-2019-0270"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kadosawa K, Morikawa T, Konishi Y. Zebra bodies without Fabry disease or hydroxychloroquine. Clin Exp Nephrol 25: 94-96, 2021.","DOI":"10.1007\/s10157-020-01965-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pradip A, Steel D, Jacobsson S, et al. High content analysis of human pluripotent stem cell derived hepatocytes reveals drug induced steatosis and phospholipidosis. Stem Cells Int 2016: 2475631, 2016.","DOI":"10.1155\/2016\/2475631"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946, 2002.","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase \u03b2 therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557, 2007.","DOI":"10.1681\/ASN.2006080816"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Dean PJ, Groshart KD, Porterfield JG, Iansmith DH, Golden EB Jr. Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol 87: 7-13, 1987.","DOI":"10.1093\/ajcp\/87.1.7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. McCloud CM, Beard TL, Kacew S, Reasor MJ. <i>In vivo<\/i> and <i>in vitro<\/i> reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages. Exp Mol Pathol 62: 12-21, 1995.","DOI":"10.1006\/exmp.1995.1002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hohman DW, Noghrehkar D, Ratnayake S. Lymphangioleiomyomatosis: a review. Eur J Intern Med 19: 319-324, 2008.","DOI":"10.1016\/j.ejim.2007.10.015"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 335: 1275-1280, 1996.","DOI":"10.1056\/NEJM199610243351704"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Martignoni G, Pea M, Rocca PC, Bonetti F. Renal pathology in the tuberous sclerosis complex. Pathology 35: 505-512, 2003.","DOI":"10.1080\/00313020310001619136"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931-940, 2003.","DOI":"10.1056\/NEJMoa021744"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Paradela de la Morena M, De La Torre Bravos M, Prado RF, et al. Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment. Transplant Proc 42: 3217-3219, 2010.","DOI":"10.1016\/j.transproceed.2010.05.064"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nishi H, Shibagaki Y, Kido R, et al. Chronic renal outcome after living donor liver transplantation. Clin Transplant 27: 90-97, 2013.","DOI":"10.1111\/ctr.12013"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ishide T, Nishi H, Ambe H, et al. Kidney failure after lung transplantation in systemic scleroderma: a case report with literature review. Renal Replace Ther 6: 44, 2020.","DOI":"10.1186\/s41100-020-00293-w"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kubal C, Cockwell P, Gunson B, et al. Chronic kidney disease after nonrenal solid organ transplantation: a histological assessment and utility of chronic allograft damage index scoring. Transplantation 93: 406-411, 2012.","DOI":"10.1097\/TP.0b013e318240e984"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Schwarz A, Haller H, Schmitt R, et al. Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues. Am J Transplant 10: 2017-2025, 2010.","DOI":"10.1111\/j.1600-6143.2010.03224.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Nangaku M, Nishi H, Fujita T. Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol 11: 107-114, 2007.","DOI":"10.1007\/s10157-007-0466-7"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 10: 1517-1523, 2010.","DOI":"10.1111\/j.1600-6143.2010.03156.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/13\/62_0882-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T03:27:13Z","timestamp":1688182033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/13\/62_0882-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0882-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"article-number":"0882-22"}}